

Metabolic Effects of Low Aflatoxin B₁ Levels on Broiler Chicks†

D. V. MAURICE,^{1*} A. B. BODINE,² AND N. J. REHRER¹

Poultry Science Department¹ and Dairy Science Department,² Clemson University, Clemson, South Carolina 29631

Received 3 September 1982/Accepted 22 December 1982

The effects of daily ingestion of aflatoxin B₁ (AFB₁) on growth, feed intake, plasma glucose, plasma cholesterol, plasma amino acids, plasma albumin, plasma ceruloplasmin, muscle amino acids, liver lipid, and bone strength were studied. For 3 weeks, beginning at an age of 2 days, broiler chicks were dosed daily per os with 50 or 100 µg of AFB₁ per kg of body weight. Body weight and feed consumption were recorded daily, and metabolic responses were determined at 3 weeks. Treatment with AFB₁ did not significantly alter body weight or feed intake. Relative liver weight showed a significant increase at the highest dose, with a significant concomitant increase in liver lipid and decrease in hepatic zinc. Relative spleen and heart weights were not affected by the toxin. Plasma glucose and cholesterol were significantly elevated at the highest dose. AFB₁ significantly decreased plasma lysine and histidine and significantly increased muscle histidine, arginine, and valine. AFB₁ decreased plasma albumin and markedly increased plasma ceruloplasmin. Dimensions of the long bones (femur and tibiotarsus) were not altered by the toxin. However, AFB₁ caused a significant linear decline in the resistance of bone to breakage ("bone breaking strength"). The results indicate that low levels of AFB₁ reduced bone strength in broiler chicks. The alterations in blood parameters indicated that AFB₁ can disrupt metabolism even at low levels.

Aflatoxins are structurally related toxic bis-furanocoumarins produced as secondary metabolites by strains of *Aspergillus flavus* and *A. parasiticus* during growth on a wide variety of agricultural commodities, including peanuts, cottonseed, and corn (32). Aflatoxin B₁ (AFB₁), the most toxic and predominant naturally occurring aflatoxin, is classified as highly to extremely toxic: for most species, it has a 50% lethal dose of <15 mg/kg of body weight (24). In addition, AFB₁ is one of the most potent hepatocarcinogens (7). AFB₁ at acutely toxic levels causes severe growth depression, weight loss, icterus, and death. The more insidious effects of long-term, low-level ingestion on several species have been studied to some extent (18, 21), but research directed specifically toward the effects of AFB₁ on avian metabolic processes has been limited to levels of >625 ppb (>625 ng/g) in feed (15). We report here the effects of low AFB₁ levels on selected chick tissue parameters.

MATERIALS AND METHODS

AFB₁ and animal treatment. Commercial AFB₁ (Sigma Chemical Co., St. Louis, Mo.) was used. A stock

solution of the toxin was prepared with propylene glycol-ethanol (9:1 [vol/vol]). The treatments consisted of 0, 50, and 100 µg of AFB₁ per kg of body weight per day. Treatments were initiated at 2 days of age and continued for 3 weeks. Chicks were weighed each afternoon (1:30 to 2:30 p.m.) and dosed per os with a pipette. The daily volume stock solution intubated was adjusted to provide the required dosage. Controls received a volume of the carrier mixture equivalent to the mean daily volume used for the highest dose.

Husbandry and necropsy. Male broiler chicks (Hubbard × Hubbard) from Whitworth Feed Mill, Lavonia, Ga., were housed in an electrically heated battery brooder with wire mesh floors. The unit was maintained in a temperature- and humidity-controlled animal room and exposed to light for 24 h. Feed and water were provided ad libitum. A standard corn-soybean diet formulated according to National Research Council nutrient specifications (20) was fed to the chicks. At the end of the study, blood samples were collected in dry heparinized tubes by frontal cardiac puncture. The tubes were held in an ice bath during blood collection. Plasma was separated by centrifugation within 30 min of collection, and each sample was divided into subsamples for various chemical determinations. Plasma samples not immediately processed were stored at -20°C until used. The birds were sacrificed by cervical dislocation, and livers, hearts, and spleens were examined, excised, and weighed. Livers and pectoralis muscle samples were frozen for chemical analyses. The right femurs and tibiotarsi were dissected, and the

† Technical contribution 2082 of the South Carolina Agricultural Experiment Station.

soft tissue was removed. Bone length and diameter were measured with calipers. After removal, femurs were kept moist with a 0.9% sodium chloride solution and maintained at 4°C for 24 h. Strength of the femur was measured by quasistatic compression to fracture with an Instron Testing Instrument (model 1122; Instron Corp., Canton, Mass.) operating at a crosshead speed of 30 mm/min.

Chemical analyses. Plasma samples used for the determination of free amino acids were processed immediately after centrifugation. Each 2.0 ml of plasma was deproteinized with 0.2 ml of 36% sulfosalicylic acid (3). We added 0.2 ml of 1 mM norleucine as an internal standard and centrifuged the mixture at 27,000 × g for 15 min. The supernatant was used for amino acid analysis. Muscle samples were delipidated with 20 volumes of chloroform-methanol (2:1 [vol/vol]) (13) and freeze dried. The lyophilized samples were digested in 6 N hydrochloric acid in vacuo at 100°C for 24 h. Amino acid profiles of plasma and muscle were determined by ion-exchange chromatography with an automatic amino acid analyzer (model K-8000 VG; Phoenix Precision Instrument Co., Phoenix, Az.) and sodium citrate buffers for elution (30). Plasma glucose was measured by the *o*-toluidine method (9), and plasma cholesterol was measured by a colorimetric method with ferric acetate and uranyl acetate (23). Plasma ceruloplasmin activity was determined by the procedure of Rice (26), with *p*-phenylenediamine as the substrate. The procedure was modified for chicken plasma by using 0.2 ml of plasma and increasing the incubation period to 1 h (31). The packed cell volume of the blood of each bird at 3 weeks of age was determined by the microhematocrit method. Serum albumin was determined by the bromocresol green method (kit no. 630; Sigma). Copper, manganese, and zinc contents of the livers were determined by atomic absorption spectrometry (model 503 spectrophotometer; The Perkin-Elmer Corp., Norwalk, Conn.) after wet oxidation with a concentrated nitric acid-perchloric acid mixture (3:1 [vol/vol]).

Statistical analysis. The three treatments were allotted in a randomized complete-block design, with four blocks per treatment. Each quarter of the battery brooder constituted a block. Within a block, each treatment was allocated to a pen of five chicks. Data were analyzed by analysis of variance. The significance of the difference between means was determined by the least-squares method. Probability values of <0.05 were considered significant. All results are expressed as means ± pooled standard errors of the means.

RESULTS

Broiler chicks showed no significant differences in body weight, feed efficiency, and relative spleen and heart weights due to daily dosing with 50 or 100 µg of AFB₁ per kg of body weight. The effects of AFB₁ on liver weight and composition, plasma metabolites, hematocrit, and bone measurements are presented in Table 1. Plasma cholesterol was significantly depressed, and plasma glucose and ceruloplasmin were significantly elevated only at the highest dose (100 µg/kg). Serum albumin, however, was

TABLE 1. Effects of AFB₁ on chick tissue parameters^a

AFB ₁ dose (µg/kg of body wt)	Plasma metabolites					Liver make-up ^b			Bone size (mm)			Bone breaking strength (kg)	
	Cholesterol (mmol/liter)	Glucose (mmol/liter)	Albumin (%)	Ceru- loplas- min (IV)	Hema- tocrit (%)	Liver wt (g)	Total lipid (%)	Zinc (µg/g)	Femur Length	Diam	Tibiotarsus Length		Diam
0	4.18 ^A	6.88 ^C	1.29 ^E	0.38 ^G	36.0	2.22 ^K	16.65 ^M	164.9 ^O	45.1	60.3	5.9	5.1	3.58 ^Q
50	4.12 ^A	7.07 ^C	1.11 ^F	0.74 ^G	35.5	2.25 ^K	16.69 ^M	131.7 ^P	45.6	61.7	6.0	5.5	3.06 ^{Q,R}
100	3.50 ^B	8.31 ^D	1.13 ^F	1.98 ^H	37.0	2.64 ^L	19.18 ^N	128.8 ^P	44.6	60.8	6.1	6.4	2.78 ^R
SEM	±0.18	±0.23	±0.04	±0.20	±0.67	±0.04	±9.52	±4.95	±0.87	±1.11	±0.30	±0.23	±0.145

^a For each set of values obtained for one parameter, values with differing superscript capital letters are significantly different (*P* < 0.05).
^b Liver lipid is expressed on a dry-matter basis; liver zinc is expressed on a fat-free dry-matter basis.

TABLE 2. Effects of AFB₁ on plasma and muscle amino acid levels

AFB ₁ dose (μg/kg of body wt)	Amino acid level ^a				
	Lysine	Histidine	Arginine	Valine	Phenylalanine
Plasma					
0	11.87 ^B	1.91 ^D	3.22	2.52	1.27 ^F
50	5.86 ^C	1.46 ^E	4.49	2.22	1.38 ^{G,F}
100	5.30 ^C	1.59 ^E	4.72	2.32	1.42 ^G
SEM	±1.06	±0.07	±0.46	±0.30	±0.03
Muscle					
0	8.37	2.92 ^H	6.16 ^J	4.56 ^L	3.68
50	8.36	2.88 ^H	6.37 ^{J,K}	4.55 ^L	3.86
100	8.35	3.32 ^I	6.73 ^K	4.86 ^M	4.07
SEM	±0.15	±0.07	±0.14	±0.08	±0.18

^a In plasma, levels are expressed as milligrams per 100 ml. In muscle samples (defatted and lyophilized), levels are expressed as milligrams per 100 mg. For each set of values obtained for one amino acid in one type of sample, values with differing superscript capital letters are significantly different ($P < 0.05$).

significantly depressed at both levels of AFB₁. Hematocrit was unaffected at either level. AFB₁ at the highest level significantly increased liver weight and lipid content. Hepatic zinc was significantly depressed even at the lowest level of AFB₁, and hepatic manganese and copper declined with increased AFB₁ ingestion. Bone measurements indicated that AFB₁ had no significant effect on linear or appositional growth of tibiotarsi and femurs. Breaking strength of wet femurs was significantly reduced at 100 μg/kg.

Table 2 summarizes the data on plasma and muscle amino acids. In general, with the exceptions of arginine and phenylalanine, the concentrations of free amino acids in plasma decreased with increased AFB₁ dosage. Plasma lysine and histidine were significantly reduced, whereas phenylalanine was significantly increased. In contrast, most muscle amino acids were elevated, and histidine, arginine, and valine were significantly reduced.

DISCUSSION

We examined the effects of low levels of AFB₁ on chick growth and selected tissue parameters. Although body weight gain and feed efficiency were not adversely affected, there were disruptions in the normal profiles of plasma metabolites, liver lipid, and bone breaking strength. In our study, chicks were given a single daily dose of AFB₁. In comparing our results with others, differences in toxicokinetics should be kept in mind. Steady-state kinetics are obtained by putting a toxin in the food, and mixed kinetics are obtained by administration of a single dose (11).

Plasma glucose showed a linear increase with

increased AFB₁ dosage, a result similar to that observed for a single dose of 2.7 mg/kg (25). This increase may be ascribed to impaired glucose utilization, since aflatoxicosis has been shown to reduce the activities of the enzymes involved in glucose metabolism (29). In agreement with earlier reports (8, 33), AFB₁ at the highest dose caused liver fat accumulation. Our observation that plasma cholesterol was reduced at 100 μg of AFB₁ per kg of body weight is consistent with the general reduction of lipogenesis (8) and impaired lipid transport (33) in chicks and specific inhibition of hepatic cholesterol biosynthesis (17) in rats by AFB₁. Hypoalbuminemia was evident even at the lowest dose of AFB₁, confirming the sensitivity of serum albumin to AFB₁ (34).

Plasma amino acids are altered in liver diseases, and the pattern of change varies with the disease (27). Plasma amino acids may be elevated because of impaired hepatic catabolism, release from necrosed hepatocytes, or muscle catabolism. In chronic liver diseases, there is an increase in the amino acids normally removed by the liver and a decrease in the amino acids principally taken up by extrahepatic tissue (19). The amino acid pattern resulting from AFB₁ administration, i.e., the significant increase in the aromatic amino acid phenylalanine and the decrease in the branched-chain amino acids isoleucine, lysine, and valine, is comparable to the common amino acid pattern observed in chronic liver damage. The increase in plasma phenylalanine suggests a decrease in the activity of phenylalanine-4-hydroxylase early in hepatic impairment by AFB₁. Our results provide no evidence of a decrease in all free amino acids (35). The

significance of the changes in muscle amino acids is not known.

Depressed plasma albumin and histidine, in conjunction with elevated ceruloplasmin, indicates a possible disruption of copper metabolism. Ceruloplasmin is the major vehicle for copper transport, and copper complexes of albumin and histidine provide an auxiliary transport system (14). The level of ceruloplasmin is normally very low in chickens but is elevated six-fold when chicks are infected or stressed by ACTH (adrenocorticotrophic hormone) or hydrocortisone (31). The precise role of AFB₁ in elevating plasma ceruloplasmin in chicks is not known but may be mediated by cortical steroids (31), metabolites of AFB₁ which mimic estrogen (2), or resialylation of asialo-ceruloplasmin by sialyl transferase (12). The last possibility is an attractive hypothesis, since AFB₁ is known to impair protein synthesis (5) and hypoalbuminemia was evident in the present study even at the lowest dose of AFB₁. The possible effect of AFB₁ on copper metabolism may also be responsible for the hepatocarcinogenicity of the toxin, since copper has been shown to protect against certain hepatocarcinogens (10).

Growth-inhibiting levels of AFB₁ have been shown to have a deleterious effect on chicken bone breaking strength, even after the effect on bone diameter is negated (16). The reduction in bone breaking strength observed in our experiment contradicts an earlier report (16) which indicated that bone breaking strength is not significantly altered at 125 µg of AFB₁ per g of feed. Bones from copper-deficient chicks fracture with less deformation (28), whereas bones from birds suffering from aflatoxicosis break with considerably more deformation (16). This implies that bones from copper-deficient chicks are brittle and bones from AFB₁-dosed chicks are pliable. These data suggest that copper metabolism alterations induced by AFB₁ cannot explain the reduction in bone breaking strength. The changes in the material properties of bone during aflatoxicosis (16) may result from changes in cholecalciferol metabolism, since AFB₁ is both hepato- and nephrotoxic. Assays of chick bone ash have demonstrated an interaction between AFB₁ and cholecalciferol resulting in bone calcification (1). However, this may be discounted because AFB₁ does not alter the hydroxylation of cholecalciferol in the livers or kidneys of chicks (4).

Hypoalbuminemia caused by AFB₁ may partially explain the reduction in hepatic zinc (5): since albumin serves as a zinc carrier, less zinc would be brought to the hepatocytes for processing (6). The effect of AFB₁ on protein synthesis may also be reflected in decreased production of metallothionein, which has been shown

to be involved in zinc homeostasis in chicks (22). Either mechanism would result in lowered sequestration of zinc by the liver.

Our results confirm previous reports on the effects of AFB₁. In addition, they clearly show that low levels of AFB₁ disrupt metabolic processes without producing overt symptoms. The apparent impairment of copper metabolism could have important consequences, since copper metalloproteins are involved in diverse physiological processes. It is conceivable that some of the symptoms associated with chronic aflatoxicosis are the result of interference with metabolic schemes involving trace element metalloproteins.

LITERATURE CITED

1. Bird, F. H. 1978. The effect of aflatoxin B₁ on the utilization of cholecalciferol by chicks. *Poultry Sci.* 57:1293-1296.
2. Blankenship, L. T., J. D. Dickey, and A. B. Bodine. 1982. *In vitro* mycotoxin binding to bovine uterine steroid hormone receptors. *Theriogenology* 17:325-331.
3. Block, W. D., M. E. Markovs, and B. F. Steele. 1966. Comparison between free amino acid levels in plasma deproteinized with picric acid and with sulfosalicylic acid. *Proc. Soc. Exp. Biol. Med.* 122:1089-1091.
4. Britton, W. M., and R. D. Wyatt. 1978. Effect of dietary aflatoxin on vitamin D₃ metabolism in chicks. *Poultry Sci.* 57:163-165.
5. Clifford, J. I., and K. R. Rees. 1967. The interaction of aflatoxins with purines and purine nucleosides. *Biochem. J.* 103:467-471.
6. Cousins, R. J. 1979. Regulatory aspects of zinc metabolism in liver and intestine. *Nutr. Rev.* 37:97-103.
7. Detroy, Q. W., E. B. Lillehoj, and A. Ciegler. 1971. Aflatoxin and related compounds, vol. 6, p. 97-108. *In A. Ciegler, S. Kadiss, and S. J. Ajl (ed.), Microbial toxins.* Academic Press, Inc., New York.
8. Donaldson, W. E., H. T. Tung, and P. B. Hamilton. 1972. Depression of fatty acid synthesis in chick (*Gallus domesticus*) liver by aflatoxin. *Comp. Biochem. Physiol.* 41B:843-847.
9. Dubowski, K. M. 1962. An *o*-toluidine method for body fluid glucose determination. *Clin. Chem.* 8:215-235.
10. Fare, G., and J. S. Howell. 1964. The effect of dietary copper on rat carcinogenesis by 3-methoxy dyes. I. Tumors induced at various sites by feeding 3-methoxy-5-aminoazobenzene and its *n*-methyl derivative. *Cancer Res.* 24:1279-1283.
11. Filov, V. A., A. A. Golubev, E. I. Liublina, and N. A. Tolokontser. 1979. *Quantitative toxicology*, p. 94-164. John Wiley & Sons, Inc., New York.
12. Fisher, G. L., and M. Shifrine. 1978. Hypothesis for the mechanism of elevated serum copper levels in cancer patients. *Oncology* 35:22-25.
13. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for isolation and purification of total lipids from animal tissues. *J. Biol. Chem.* 226:497-509.
14. Frieden, E., and H. S. Hsieh. 1976. Ceruloplasmin: the copper transport protein with essential oxidase activity. *Adv. Enzymol.* 44:187-236.
15. Hamilton, P. B. 1977. Interrelationships of mycotoxins with nutrition. *Fed. Prod.* 36:1899-1902.
16. Huff, W. E., J. A. Doerr, P. B. Hamilton, D. D. Hamann, R. E. Petersen, and A. Ciegler. 1980. Evaluation of bone strength during aflatoxicosis and ochratoxicosis. *Appl. Environ. Microbiol.* 40:102-107.
17. Kato, R., K. Onoda, and Y. Omori. 1969. Effect of aflatoxin B₁ on the incorporation of ¹⁴C-acetate into

- cholesterol by rat liver. *Experientia* 25:1026.
18. **Keyl, A. C., A. N. Booth, M. S. Masir, M. R. Gumbmann, and W. E. Gagne.** 1970. Chronic effects of aflatoxin in farm animal feeding studies, p. 72-75. Proceedings of the First U.S.-Japan Conference on Toxic Microorganisms. U.S. Department of the Interior, Wash., D.C.
 19. **Mezey, E.** 1982. Liver disease and protein needs. *Annu. Rev. Nutr.* 2:21-50.
 20. **National Research Council.** 1977. Nutrient requirements of poultry. National Academy of Science, Washington, D.C.
 21. **Newberne, P. M., and W. H. Butler.** 1969. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals. *Cancer Res.* 29:236-250.
 22. **Oh, S. H., H. NaKaue, J. T. Deagen, P. D. Whanger, and G. H. Arscott.** 1979. Accumulation and depletion of zinc in chick tissue metallothioneins. *J. Nutr.* 109:1720-1729.
 23. **Parekh, A. C., and D. H. Jung.** 1970. Cholesterol determination with ferric acetate-uranium acetate and sulfuric acid-ferrous sulfate reagents. *Anal. Chem.* 42:1423-1427.
 24. **Patterson, D. S. P.** 1973. Metabolism as a factor in determining toxic action of aflatoxins in different animal species. *Food Cosmet. Toxicol.* 11:287-294.
 25. **Raj, H. G., R. Shankaran, and T. A. Venkatasubramanian.** 1970. Metabolic effects of aflatoxin in one-day-old chicks. *Ind. J. Biochem.* 7:55-56.
 26. **Rice, E. W.** 1962. Standardization of ceruloplasmin activity in terms of international enzyme units. *Anal. Biochem.* 3:452-456.
 27. **Rosen, H. M., N. Yoshimura, J. M. Hodman, and J. E. Fischer.** 1977. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. *Gastroenterology* 72:483-487.
 28. **Rucker, R. B., R. S. Riggins, R. Laughlin, M. M. Chan, M. Chen, and K. Tom.** 1975. Effects of nutritional copper deficiency on the biomechanical properties of bone and arterial elastin metabolism in the chick. *J. Nutr.* 105:1062-1070.
 29. **Shankaran, R., H. G. Raj, and T. A. Venkatasubramanian.** 1970. Effect of aflatoxin on carbohydrate metabolism in chick liver. *Enzymologia* 39:371-378.
 30. **Spackman, D. H., W. H. Stein, and S. Moore.** 1958. Automatic recording apparatus for use in the chromatography of amino acids. *Anal. Chem.* 30:1190-1206.
 31. **Starcher, B., and C. H. Hill.** 1965. Hormonal induction of ceruloplasmin in chicken serum. *Comp. Biochem. Physiol.* 15:429-434.
 32. **Stoloff, L.** 1977. Aflatoxins—an Overview, p. 7-28. *In* J. V. Rodricks, C. W. Hessletine, and M. Mehlman (ed.), *Mycotoxins in human and animal health*. Pathotox Publishers, Inc., Park Forest South, Ill.
 33. **Tung, H. T., W. E. Donaldson, and P. B. Hamilton.** 1972. Altered lipid transport during aflatoxicosis. *Toxicol. Appl. Pharmacol.* 22:97-104.
 34. **Tung, H. T., R. D. Wyatt, P. Thaxton, and P. B. Hamilton.** 1975. Concentrations of serum proteins during aflatoxicosis. *Toxicol. Appl. Pharmacol.* 34:320-326.
 35. **Voigt, M. N., R. D. Wyatt, J. C. Ayres, and P. E. Koehler.** 1980. Abnormal concentrations of B vitamins and amino acids in plasma, bile and liver of chicks with aflatoxicosis. *Appl. Environ. Microbiol.* 40:870-875.